News

October 31, 2017

Health Canada OKs Imbruvica for Treating Chronic Graft-Versus-Host Disease

News

Janssen‘s Imbruvica (ibrutinib) has been approved by Health Canada for treating chronic graft-versus-host disease (cGVHD), a life-threatening condition that some patients develop after a stem cell transplant. Following a priority ... Read more

October 27, 2017October 27, 2017

FDA Clears Way for Denovo to Launch Phase 3 Trial of DB102 for DLBCL Patients in US

News

The U.S. Food and Drug Administration (FDA) has given Denovo Biopharma the green light to advance its investigational drug DB102 into a Phase 3 clinical trial for diffuse large B-cell lymphoma ... Read more

October 26, 2017

ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin’s Lymphoma

News

ADC Therapeutics, a company specializing in the development of antibody drug conjugates (ADCs) for several cancer indications, has raised $200 million through a private placement. The financing will be used ... Read more

October 25, 2017

Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds

News

Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL). Representatives from ... Read more

October 24, 2017October 24, 2017

Immune Design’s G100 Receives EMA’s Orphan Drug Designation for Follicular Non-Hodgkin’s Lymphoma

News

The European Medicines Agency (EMA) has granted G100 orphan drug status for the treatment of follicular non-Hodgkin’s lymphoma, Immune Design, the drug’s developer, announced in a press release. The EMA orphan drug designation – ... Read more

October 23, 2017October 23, 2017

French Researchers Develop Quick, Cost-Effective Test to Detect DLBCL Subtypes

News

A newly developed assay can rapidly and accurately recognize different subtypes of diffuse large B-cell lymphoma (DLBCL), providing useful diagnostic information that could help doctors match tumors with the right ... Read more

October 20, 2017October 21, 2017

Researchers Identify Enzyme as New Target for Treating Classical Hodgkin’s Lymphoma

News

An enzyme called monoamine oxidase-A (MAO-A) contributes to the growth of classical Hodgkin’s lymphoma cells but not other lymphoma cells, a study reports. It also indicated that a combination of ... Read more

October 19, 2017

FDA Approves Yescarta, First CAR T-cell Therapy for Lymphoma

News

The U.S. Food and Drug Administration (FDA) approved Kite Pharma‘s Yescarta (axicabtagene ciloleucel) for the treatment of relapsed or refractory large B-cell lymphoma patients who received at least two prior ... Read more

October 18, 2017October 18, 2017

Incysus Advances T-Cell Therapy into Phase 1 Trial for Blood Cancers

News

Incysus and the University of Alabama at Birmingham (UAB) are advancing the company’s investigational gamma-delta (γδ) T-cell therapy into a Phase 1 clinical study for the treatment of leukemia and lymphoma ... Read more

October 17, 2017October 17, 2017

Primary Care Programs for Cancer Survivors Are Still Lacking, Report Reveals

News

Primary care is not set up to meet the specific healthcare needs of cancer survivors, according to a study by researchers at Rutgers University. The study illustrates how efforts to ... Read more